

ASX Release

7 February 2025

Sigma FY25 trading update

Sigma Healthcare Limited (ABN 15 088 417 403) has today upgraded its full year normalised EBIT guidance for the year ending 31 January 2025 to \$64 to \$70 million, up from the \$50 to \$60 million range previously guided in September 2024.

The upgrade follows improved operational performance, including the strong execution of the new Chemist Warehouse supply contract that commenced on 1 July 2024, demonstrating our ability to efficiently absorb volume growth.

Subject to audit completion, FY25 Statutory NPAT will be significantly impacted by non-recurring costs relating to the merger, including impacts of changes to existing performance rights as approved at the Sigma EGM.

Sigma's full year audited results are anticipated to be released to the ASX in mid March 2025.

This announcement is authorised by order of the Board.

For more information contact:

Gary Woodford
Head of Corporate Affairs
gary.woodford@sigmahealthcare.com.au
0417 399 204

Steve Dabkowski
Blue Dot Media
steve@bluedot.net.au
0419 880 486

For personal use only